Arvinas (ARVN) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Arvinas (ARVN) over the past year, gaining 48.1% versus a loss of 23.0%. Over five years, OVID leads with a -35.0% price change compared with -91.2% for ARVN. Arvinas is the larger company by market cap ($496.8 million vs $477.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | OVID |
|---|---|---|
| Share price | $7.70 | $2.45 |
| Market cap | $496.81M | $477.50M |
| 1-day change | +2.53% | +4.49% |
| YTD return | -36.68% | +43.56% |
| 1-year return | -22.97% | +48.10% |
| 5-year return | -91.18% | -35.00% |
| P/E ratio (TTM) | 29.62 | — |
| EPS (TTM) | $0.26 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $3.11 |
| 52-week low | $6.97 | $1.18 |
| Distance from 52-week high | -46.93% | -21.26% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +80.91% | +146.22% |
| Average volume | 788.21K | 1.57M |
| Shares outstanding | 64.52M | 195.30M |
| Employees | 246 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed ARVN by 71.1 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ARVN vs OVID FAQ
Which is bigger, Arvinas or Ovid Therapeutics?
Arvinas (ARVN) is larger, with a market capitalization of $496.81M compared with $477.50M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, ARVN or OVID?
OVID returned +48.10% over the past 12 months, compared with -22.97% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.